Nour-Eldin raises several interesting points which can be answered from studies on the molecular genetics of haemophilia A and from recent work on intracellular transport processes involved in the secretion of glycoproteins.
Most cases of severe haemophilia A are due to major gene lesions at the F8 locus including inversions, deletions, premature stop codons and splicing errors. In these cases no detectable factor VIII is present in blood. Few tissue studies have ever been performed in haemophiliacs, for obvious reasons: and in any case the overwhelming procoagulant in tissue is tissue factor itself, which is of course normal in haemophilia A, and by triggering the direct activation of factor X, apparently 'corrects' the clotting defect in factor VIII or factor IX deficient plasma. This explains the claims made for the presence of 'factor VIII activity' in haemophilic tissue.
Most cases of mild haemophilia A are due to missense mutations and they usually have markedly reduced levels of factor VIII antigen as well as activity in their plasma, suggesting failure to correctly process and export mutant protein from hepatocytes. This would fit Nour-Eldin's proposal of 'inhibited release from tissue'.
For an up to date compilation of mutations in haemophilia, please visit our database at http: / /europium.mrc.rpms. ac. uk where there is also a review of the molecular pathology of haemophilia A.
In regard to genes involved in regulating factor VIII production, we have recently mapped a gene for combined factor V and factor VIII deficiency (CF5F8D) (an autosomal recessive disorder) to chromosome 1 8q2 11. Further work by Ginsburg and colleagues has revealed the gene to be ERGIC-53, encoding a previously characterized resident protein of the endoplasmic reticulum-Golgi intermediate compart-ment2.
Most patients with CF5F8D have null mutations in this gene (own observations). ERGIC-53 is a mannose binding lectin thought to be involved in transporting heavily glycosylated proteins (such as factors V and VIII) from the endoplasmic reticulum to the Golgi complex.
Nour-Eldin's idea may therefore be applicable to CF5F8D by means of gene therapy, but is unlikely to be used for a relatively mild bleeding disorder (patients with residual levels of factor V and VIII of 5% or more). The bulk of patients with classical haemophilia will have to continue to be treated by intravenous replacement therapy until safe gene therapy or gene correction therapy can be used to provide them with a functioning gene for normal wild type factor VIII (or factor IX in haemophilia B). The immune response to introduced transgenes is a major limitation at present. (Figure 1 ), sending only this distal portion to Owen. Why he did so is mysterious but the drawing and the portion in the College correspond exactly. Martin's second letter runs to five sheets of large folio with an operative drawing of the 'file sound' placed to reduce a stone at the base of his bladder. As Martin emphasized, only the convex part of the tip was file-like; inspection confirms superficial cross-hatching of this specific area.
Space prevents a full description of his illness but at the end of 1783 Martin was in much better health having removed some 3-4 ounces of gravel and sand by silver catheter and by filing a stone whenever it
